CUV 0.00% $30.65 clinuvel pharmaceuticals limited

company presentation

  1. 22,691 Posts.
    PDF, 19 pages:

    "Phase I/IIa clinical trial successfully completed at Royal Adelaide Hospital in March 2002.
    �� Phase IIb “sunburn” trial will finish mid September 2003 with preliminary results due early November.

    The company fully expects results will show that
    sunburn damage is markedly reduced following Melanotan treatment.

    �� Sustained release formulation developed in collaboration with SRI (Alabama, USA). This (new) formulation in the form of a small implant is designed to be placed under the skin.

    �� Phase I/II (human) clinical trials will begin at Q-Pharm, Brisbane in November.

    �� Collaborative agreement with CollaGenex and Thomas Sköld to develop a
    topical formulation using Restoraderm™ technology".
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Mkt cap ! $1.514B
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 332 $31.50

Sellers (Offers)

Price($) Vol. No.
$29.03 339 3
View Market Depth
Last trade - 10.02am 23/04/2021 (20 minute delay) ?
0.000 ( 0.03 %)
Open High Low Volume
$30.50 $30.51 $30.47 119
Last updated 10.21am 23/04/2021 (live) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.